Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Sirona Biochem Corp. (V:SBM)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for SBM within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 11, 2019 09:00 ET
Sirona Biochem Adopts Shareholder Rights Plan
VANCOUVER, Sept. 11, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that its board of directors has approved the adoption of a shareholder rights plan (the "Rights Plan"). The Rights Plan is subject to acceptance by the TSX Venture Exchange ("TSXV") and ratification by Sirona's shareholders within six months. If the shareholders do not ratify the Rights Plan at the AGM, the Rights Plan and all the rights outstanding at the time will terminate.
Read full article
Jul 10, 2019 09:00 ET
Sirona Biochem Announces Successful Close of Oversubscribed Private Placement
VANCOUVER, July 10, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) ("Sirona") is very pleased to announce today that it closed its private placement (Private Placement") as oversubscribed for gross proceeds of $1,500,000 CAD. The Private Placement consists of 3,750,000 units, (the "Units") at a price of $0.40 per Unit.  Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.60 per share subject to an accel
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.38
--
--
Price to Sales - TTM
121.49
16.11
12.72
Price to Book - most recent quarter
--
3.11
2.78
Price to Cash Flow per share - TTM
--
--
12.38
Price to Free Cash Flow per share - TTM
--
4.12
18.61
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Aug 31, 2019122,223-123,376
Aug 15, 2019245,59930,426
Jul 31, 2019215,173-229,684
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Sirona Biochem Corp. is a Canada-based development-stage cosmetic ingredient and drug discovery company with a technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. It is engaged in the development of cosmetic and pharmaceutical active ingredients, which are licensed to its partners. The Company has six product lines: SGLT2 Inhibitor, Skin Lightener I, GlycoProteMin-Anti aging, Anti-inflammatory, Anti-infective and Skin Lightener II. Its development is focused on three programs: therapeutics, which includes diabetes, anti-inflammatories and anti-infectives; cosmeceuticals, which includes anti-aging and depigmenting agents (skin lighteners), and biological ingredients, which includes inducers and adjuvants for biological development and preservation. The Company, through TFChem S.A.R.L. (TFC), is engaged in using fluorine atom properties to develop glycomimetic compounds.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $SBM.CA SBM.V